Teleflex Q2 Earnings Call Highlights

Impact · against what's priced in

Teleflex shares are likely to see positive pressure due to a significant raise in full-year EPS guidance and a $1 billion shareholder return plan, which outweigh the operational headwinds. While integration delays in the Vascular Intervention business have led to a lower revenue growth outlook, the reduction in net leverage to 1.9x improves the company's risk profile.

TFX+0.40

No priced-in read yet

In context

The company raised its full-year adjusted EPS guidance to $6.90–$7.20 from $6.25–$6.55 and announced a $1 billion shareholder return plan, though these gains are partially offset by lowering revenue growth outlook to 3.5%–4.5% due to integration delays in the Vascular Intervention business.

• m and a
• healthcare
• earnings
• guidance
• TFX
• debt reduction
• divestitures
• integration
• medical devices
• share buybacks

Search tags